Literature DB >> 12404513

Type-2 astrocyte-like cells are more resistant than oligodendrocyte-like cells against non-N-methyl-D-aspartate glutamate receptor-mediated excitotoxicity.

Yoko Yamaya1, Akira Yoshioka, Shinji Saiki, Natsuko Yuki, Genjiro Hirose, David Pleasure.   

Abstract

Glutamate causes excitotoxicity via non-N-methyl-D-aspartate (NMDA) glutamate receptors (GluR) in oligodendrocytes. Because both oligodendrocytes and type 2 astrocytes are differentiated from oligodendrocyte-type 2 astrocyte (O-2A) progenitor cells, we investigated whether astrocytes are also vulnerable to non-NMDA GluR-mediated excitotoxicity. For these studies, oligodendrocyte-like cells (OLC) and type 2 astrocyte-like cells (2ALC) were derived from CG-4 cells, an immortalized rat O-2A progenitor cell line. About 50% of 2ALC were positive for glial fibrillary acidic protein and 90% were positive for A2B5, verifying that these cells have an type 2 astrocytic phenotype. A 24-hr exposure of OLC to 2 mM kainate, an activator of non-NMDA GluR, caused cell damage as shown by the release of lactate dehydrogenase. The extent of kainate-induced OLC damage was increased by cyclothiazide. In contrast, exposure of 2ALC to 2 mM kainate alone did not induce injury, though mild 2ALC injury was elicited by exposure to 2 mM kainate plus 100 microM cyclothiazide. Furthermore, we found that the kainate induced Ca(2+) uptake by 2ALC was 27.5% of that induced by kainate in OLC. Finally, both OLC and 2ALC expressed non-NMDA GluR subunit mRNAs, including GluR2, GluR3, GluR4, GluR6, GluR7, KA1, and KA2, but quantitative Western blot analysis revealed higher immunodetectable GluR2 and lower immunodetectable GluR3 and GluR4 in 2ALC than in OLC. Together, these results suggest that astrocytes are relatively resistant to non-NMDA GluR-mediated excitotoxicity because they have a higher expression of GluR2 and lower expression of GluR3 and GluR4. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404513     DOI: 10.1002/jnr.10425

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  5 in total

1.  Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex.

Authors:  Delia M Talos; Pamela L Follett; Rebecca D Folkerth; Rachel E Fishman; Felicia L Trachtenberg; Joseph J Volpe; Frances E Jensen
Journal:  J Comp Neurol       Date:  2006-07-01       Impact factor: 3.215

2.  Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex.

Authors:  Delia M Talos; Rachel E Fishman; Hyunkyung Park; Rebecca D Folkerth; Pamela L Follett; Joseph J Volpe; Frances E Jensen
Journal:  J Comp Neurol       Date:  2006-07-01       Impact factor: 3.215

3.  Dysmyelinated axons in shiverer mice are highly vulnerable to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity.

Authors:  David Pitt; Ernesto Gonzales; Anne H Cross; Mark P Goldberg
Journal:  Brain Res       Date:  2009-11-04       Impact factor: 3.252

Review 4.  Researching glutamate - induced cytotoxicity in different cell lines: a comparative/collective analysis/study.

Authors:  Aristeidis A Kritis; Eleni G Stamoula; Krystallenia A Paniskaki; Theofanis D Vavilis
Journal:  Front Cell Neurosci       Date:  2015-03-17       Impact factor: 5.505

5.  Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.

Authors:  Lillian M Toomey; Carole A Bartlett; Nikolas Gavriel; Terence McGonigle; Maimuna Majimbi; Gopana Gopalasingam; Jennifer Rodger; Melinda Fitzgerald
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.